GO:0070937 CRD-mediated mRNA stability complex

The CRD-mediated mRNA stability complex (GO:0070937) is a cellular component defined by its capacity to bind mRNA molecules that contain a coding region instability determinant (CRD) and to promote their stabilization. This complex sits at the interface of RNA processing and post-transcriptional gene regulation, where it determines whether specific transcripts are rapidly degraded or preserved for translation. Understanding this complex is critical because mRNA half-life is a major determinant of protein expression, and its misregulation can drive oncogenic programs and other disease states [1,2]. The complex was initially characterized through studies of c-myc mRNA stability, where IGF2BP1-associated cytoplasmic RNPs were shown to bind the CRD and protect the transcript from degradation. Subsequent work has expanded the known components to include HNRNPU, SYNCRIP/HNRNPQ, YBX1, and DHX9, forming a multi-protein RNP machine that recognizes CRD elements in a sequence-specific manner. For researchers, GO:0070937 provides a precise ontological handle for annotating proteins, designing perturbation experiments, and interpreting transcriptomic and proteomic data in the context of mRNA stability control. The complex is particularly relevant to cancer biology, where stabilization of transcripts such as c-myc can sustain proliferative signaling and contribute to tumor progression [1,2]. This article synthesizes the authoritative QuickGO definition with verified PubMed literature to provide a research-grade overview of the CRD-mediated mRNA stability complex, its components, mechanisms, disease links, and the experimental models used to study it [1,2].

The CRD-mediated mRNA stability complex is a protein complex that binds to mRNA molecules containing a coding region instability determinant (CRD) and promotes their stabilization. In human cells, the complex may consist of IGF2BP1, HNRNPU, SYNCRIP/HNRNPQ, YBX1, and DHX9. Its synonym, coding-region determinant of instability-mediated mRNA stability complex, reflects its function in counteracting CRD-directed decay.

The CRD-mediated mRNA stability complex is important because it directly controls the half-life of transcripts that carry CRD elements, thereby influencing protein expression programs that drive cell proliferation, differentiation, and stress responses. By stabilizing mRNAs such as c-myc, the complex can amplify oncogenic signaling, making it a potential target for therapeutic intervention in cancers where c-myc or other CRD-containing transcripts are overexpressed [1,2]. Moreover, the complex serves as a paradigm for understanding how cytoplasmic RNP granules recognize sequence-specific instability determinants and protect them from decay machinery. Researchers studying post-transcriptional regulation, cancer biology, and RNA-protein interactions need to understand this complex to interpret mRNA stability data and to design experiments that perturb its function [1,2].

The following genes and proteins are known or proposed components and regulators of the CRD-mediated mRNA stability complex, based on verified literature.

The CRD-mediated mRNA stability complex is regulated at multiple levels, including the availability of its RNA-binding protein components and the presence of CRD-containing target mRNAs. IGF2BP1-associated cytoplasmic RNPs are dynamically assembled and can be influenced by cellular signaling and stress conditions. The complex function is also linked to broader post-transcriptional regulatory networks, including autophagic flux and MAPK cascade inhibition in cancer contexts. However, the precise upstream signals that control complex assembly and activity remain an active area of research.

The CRD-mediated mRNA stability complex is directly implicated in cancer through its ability to stabilize c-myc mRNA, a key oncogene that drives cell proliferation and survival. IGF2BP1-associated cytoplasmic RNPs bind the CRD in c-myc mRNA and protect it from degradation, leading to increased c-myc protein levels. This mechanism can contribute to tumorigenesis and cancer progression, making the complex a potential therapeutic target [1,2]. In cervical cancer, post-transcriptional regulation of CARMN has been linked to autophagic flux blockade and MAPK cascade inhibition, highlighting the broader relevance of mRNA stability control in cancer biology.

Dysregulation of mRNA stability is a common feature of many diseases, and the CRD-mediated mRNA stability complex represents a specific node where this regulation can go awry. By controlling the half-life of CRD-containing transcripts, the complex influences protein expression programs that can contribute to disease phenotypes. Understanding how the complex is altered in disease states may reveal new biomarkers or therapeutic opportunities [1,2].

While the best-characterized role of the CRD-mediated mRNA stability complex is in cancer through c-myc stabilization, the complex may also function in other contexts where CRD-containing mRNAs are expressed. Further research is needed to determine whether the complex contributes to diseases such as neurodegeneration or developmental disorders, where mRNA stability defects have been observed.

RNA stability assays, such as actinomycin D treatment followed by quantitative PCR, are used to measure the half-life of CRD-containing mRNAs in the presence or absence of the complex. These assays can be performed in cells with CRISPR-mediated knockout of complex components to determine their contribution to mRNA stabilization.

RNA immunoprecipitation (RIP) followed by sequencing or mass spectrometry can identify mRNAs bound by the complex and its protein interactors. Proteomic approaches can reveal the composition of the complex and its dynamic assembly in response to cellular signals.

RNA-seq of cells with perturbed complex components can reveal global changes in mRNA abundance and stability. This approach helps identify the repertoire of CRD-containing transcripts regulated by the complex.

Fluorescence microscopy of tagged complex components can visualize the formation and localization of cytoplasmic RNP granules. Live-cell imaging can track the dynamics of complex assembly and mRNA binding.

Researchers studying CRD-mediated mRNA stability complex-related genes often need to determine whether a candidate gene is causally involved in mRNA stabilization, how specific mutations affect complex assembly, and which transcripts are regulated. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.

The CRD-mediated mRNA stability complex (GO:0070937) is a critical post-transcriptional regulator that binds CRD-containing mRNAs and protects them from degradation, thereby influencing protein expression programs in health and disease. Its components, including IGF2BP1, HNRNPU, SYNCRIP/HNRNPQ, YBX1, and DHX9, cooperate to stabilize transcripts such as c-myc, linking the complex to cancer and other diseases [1,2]. Understanding this complex requires integrated approaches, from CRISPR-based perturbation to RNA stability assays and proteomics. EDITGENE offers a full suite of CRISPR services to accelerate research on this complex and its role in disease.